Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel. [electronic resource]
Producer: 20160506Description: 953-66 p. digitalISSN:- 1432-0738
- Antigens, CD -- genetics
- Biotransformation
- Breast Neoplasms -- genetics
- Cell Proliferation -- drug effects
- Dose-Response Relationship, Drug
- Enzyme Activation
- Extracellular Signal-Regulated MAP Kinases -- metabolism
- Female
- Genetic Engineering -- methods
- Humans
- Hypoglycemic Agents -- metabolism
- Insulin -- analogs & derivatives
- Insulin Glargine -- toxicity
- MCF-7 Cells
- Proto-Oncogene Proteins c-akt -- metabolism
- RNA Interference
- Receptor, IGF Type 1
- Receptor, Insulin -- agonists
- Receptors, Somatomedin -- agonists
- Signal Transduction -- drug effects
- Time Factors
- Transfection
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.